Pirtobrutinib

Pirtobrutinib is a Kinase Inhibitor. The mechanism of action of pirtobrutinib is as a Bruton’s Tyrosine Kinase Inhibitor, and P-Glycoprotein Inhibitor, and Cytochrome P450 2C8 Inhibitor, and Cytochrome P450 2C19 Inhibitor, and Cytochrome P450 3A Inhibitor, and Breast Cancer Resistance Protein Inhibitor. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Pirtobrutinibum, (S)-5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1, 1 and 1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide. Its PubChem CID is 129269915.

CAS No 2101700-15-4
Molecular Formula C22H21F4N5O3
Molecular Weight 479.4 g/mol
Synonyms 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide

Frequently Asked Questions